TRALI Policy

The Blood Center follows current industry guidelines to reduce the risk of Transfusion Related Acute Lung Injury (TRALI) in recipients who receive high volume plasma products.

- Allogeneic or directed donors must answer the following questions on the Donor Registration Record (DRR).

  _____

  Female donors: Have you ever been pregnant or are you pregnant now?

  Male & Female donors: Have you ever had a blood transfusion?

  _____

- High volume plasma products and whole blood for allogeneic transfusion should be from
  - Donors who have never been transfused with cellular blood products
  - Donors who have been transfused with cellular blood products and have been tested for HLA antibodies since their most recent transfusion and results interpreted as negative
  - Females who have not been pregnant
  - Females who have been pregnant and have been tested for HLA antibodies since their most recent pregnancy and results interpreted as negative
- If either question is answered in the affirmative by a donor, the following blood products will not be produced unless the donor has been screened for HLA Antibodies and results interpreted as negative
  - Fresh Frozen Plasma (FFP) obtained from whole blood
  - FFP obtained from apheresis
    - plasmapheresis
    - plasma collected concurrently with a cellular component (red cells or platelets)
  - Plasma, Cryoprecipitate Reduced (i.e., Cryo-poor plasma) obtained from whole blood
  - Plasma Frozen Within 24 Hours After Phlebotomy (PF24) obtained from whole blood or apheresis

- Plasma Frozen Within 24 Hours After Phlebotomy Held At Room Temperature Up To 24 Hours After Phlebotomy (PF24RT24) obtained from apheresis
- Thawed Plasma from any of the above products
- Liquid Plasma
- Whole Blood (if designated for transfusion as whole blood rather than for component preparation)

- **Donors testing reactive for HLA antibodies are deferred from donating high volume plasma products** and are notified by the Medical/Legal Department of their donation status
- **Donors with blood products implicated in a possible TRALI case and, upon testing are found to be reactive for anti-HLA antibodies, are permanently deferred from allogeneic blood donations.**
- **Donors who are the only provider of blood components to a patient with a suspected case of TRALI, and do not test reactive for anti-HLA antibodies, are permanently deferred from allogeneic blood donations if determined as such following Medical Director review.**

- The Blood Center will manufacture Recovered Plasma for further manufacturing

Document Change Control:

( ) Major Change (Change Control & Risk Analysis Required)		Change Control Submission Date:
Department:	Submitted By:	Change Control Number: